By Dr Charlotte Rose Lemech

Journal articles

Lemech C; Infante J; Arkenau HT, 2013, 'Combination molecularly targeted drug therapy in metastatic melanoma: Progress to date', Drugs, 73, pp. 767 - 777, http://dx.doi.org/10.1007/s40265-013-0049-8

Lemech CR; Arkenau HT, 2013, 'Rationally Designed Drug Development beyond BRAF Inhibition in Metastatic Cutaneous Melanoma', World Journal of Cancer Research

Saggese M; Dua D; Simmons E; Lemech C; Arkenau HT, 2013, 'Research biopsies in the context of early phase oncology studies: Clinical and ethical considerations', Oncology Reviews, 7, pp. 34 - 37, http://dx.doi.org/10.4081/oncol.2013.e5

Arkenau H-T; Saggese M; Lemech C, 2012, 'DABRAFENIB MESYLATE Serine/Threonine-Protein Kinase B-raf Inhibitor, Oncolytic', DRUGS OF THE FUTURE, 37, pp. 469 - 474, http://dx.doi.org/10.1358/dof.2012.037.07.1820872

Soria J-C; Gan HK; Arkenau H-T; Blagden SP; Plummer R; Ranson M; Evans TRJ; Zalcman G; Bahleda R; Hollebecque A; Lemech C; Brown J; Peddareddigari VGR; Gibson D; Murray SC; Nebot N; Mazumdar J; Fleming RA; Millward M, 2012, 'Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.', Journal of Clinical Oncology, 30, pp. 3000 - 3000, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.3000

Lemech CR; Fontela A; Arkenau H-T; Chin MTM; Li S; Liauw WS; Thomas D; De Souza PL, 2012, 'Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours.', Journal of Clinical Oncology, 30, pp. e13585 - e13585, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e13585

Arkenau HT; Saggese M; Lemech C, 2012, 'Advanced gastric cancer: Is there enough evidence to call second-line therapy standard?', World Journal of Gastroenterology, 18, pp. 6376 - 6378, http://dx.doi.org/10.3748/wjg.v18.i44.6376

Arkenau HT; Saggese M; Lemech C, 2012, 'Dabrafenib mesylate: Serine/threonine-protein kinase B-raf inhibitor oncolytic', Drugs of the Future, 37, pp. 469 - 474, http://dx.doi.org/10.1358/dof.2012.037.07.1820872

Lemech C; Arkenau HT, 2012, 'Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities', Clinical Medicine Insights Oncology, 6, pp. 53 - 66, http://dx.doi.org/10.4137/CMO.S5855

Lemech C; Infante J; Arkenau HT, 2012, 'The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: Rationale and latest evidence', Therapeutic Advances in Medical Oncology, 4, pp. 61 - 73, http://dx.doi.org/10.1177/1758834011432949

Arkenau, H.-T. ; Saggese, M. ; Lemech, C. , 2012, 'Dabrafenib. Serine/threonine-protein kinase B-raf inhibitor, Oncolitic.', Drugs of the Future, 37, pp. 0469 - 0469, http://dx.doi.org/10.1358/dof.2012.37.7.1820872

Lemech C; Arkenau HT, 2011, 'Biomarkers in advanced colorectal cancer: Challenges in translating clinical research into practice', Cancers, 3, pp. 1844 - 1860, http://dx.doi.org/10.3390/cancers3021844

Anglesio MS; George J; Kulbe H; Friedlander M; Rischin D; Lemech C; Power J; Coward J; Cowin PA; House CM; Chakravarty P; Gorringe KL; Campbell IG; Australian Ovarian Cancer Study Group ; Okamoto A; Birrer MJ; Huntsman DG; de Fazio A; Kalloger SE; Balkwill F; Gilks CB; Bowtell DD, 2011, 'IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.', Clin Cancer Res, 17, pp. 2538 - 2548, http://dx.doi.org/10.1158/1078-0432.CCR-10-3314

Conference Papers

Lemech CR; Humphries TG; Kichenadasse G; Richardson GE; Nagrial A; Teng C; Liu J; Joshua A; Yeo B; Cohen H; Bray C; Wang Y; Mo J; Harvey K; Zhang H; Ling Z; King N; Chal J; Ding J; Cioffi M; Maurer M; Hofmeister RJ; Getts D; Swarbrick A; Cosman R, 2025, '1342 First-in-human dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and initial efficacy of mRNA-LNP MT-302 in vivo CAR therapy in solid tumors', BMJ, pp. a1583 - a1583, presented at Late-Breaking Abstracts, http://dx.doi.org/10.1136/jitc-2025-sitc2025.1342

Ganju V; Lemech CR; Wilkinson K; Morris M; Li M; Zhu Y; Hu Y; Liu Y; Qiu Q; Jiang J; Zhuang S; Lu H, 2025, '596 A first-in-human study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the LILRB2 inhibitor ES009 in patients with advanced solid tumors', in Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, pp. A677 - A677, presented at SITC 40th Annual Meeting (SITC 2025) Abstracts, http://dx.doi.org/10.1136/jitc-2025-sitc2025.0596

Lemech C; Wei J; O’Neill S; Huang N; Goh J; McCarthy N; Park JJ; Parsonson A; Xu T, 2024, '1496 JSKN033, an innovative subcutaneous-injected fixed-dose combination (FDC) of biparatopic anti-HER2 antibody drug conjugate (ADC) and PD-L1 inhibitor in advanced solid tumor', BMJ, pp. a1725 - a1725, presented at Late-Breaking Abstracts, http://dx.doi.org/10.1136/jitc-2024-sitc2024.1496

Fu S; Mckean M; Falchook GS; Barve M; Chee C-E; Lemech C; Tan TJ; Meniawy T; Hernandez-Guerrero T; Wang W; Baakili A; Marina N; Abbadessa G; Gastine S; Wang R; Calvo E, 2024, '196 Utilizing pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers to support recommended phase 2 dose (RP2D) selection for phase 1 study of SAR444245 (SAR’245) in patients with advanced solid tumors', BMJ, pp. a224 - a224, presented at Regular and Young Investigator Award Abstracts, http://dx.doi.org/10.1136/jitc-2024-sitc2024.0196

To MD; Atkinson V; Bedard P; Brenner W; Brown J; Coello M; Daud A; Ebrahimizadeh W; Kataria H; Lee K-W; Kim ST; Lemech C; Karanam SM; Margolin KA; Merchant R; Oh D-Y; Park J; Segota Z; Shim B; Thomas S; Twardowski P; Winer I; Wong MK; Yavari A; Siu LL; Tawbi H; Ascierto P, 2024, '684 Results from ABILITY-1 monotherapy dose escalation and ongoing monotherapy expansion with MDNA11, a long-acting ‘beta-enhanced not-alpha’ IL-2 superkine, in patients with advanced solid tumors', BMJ, pp. a785 - a785, presented at Regular and Young Investigator Award Abstracts, http://dx.doi.org/10.1136/jitc-2024-sitc2024.0684

To MD; Merchant R; Atkinson V; Bedard P; Brenner W; Coello M; Antras JF; Galligan C; Lemech C; Lloyd P; Karanam SM; Margolin K; Mathew M; Prawira A; Thomas S; Twardowski P; Yavari A; Merchant F, 2023, '760 Interim PK/PD, safety and efficacy data of monotherapy dose escalation of a phase 1/2 study with MDNA11 in patients with advanced solid tumors', BMJ, pp. a856 - a856, presented at Regular and Young Investigator Award Abstracts, http://dx.doi.org/10.1136/jitc-2023-sitc2023.0760

Lee DH; Roohullah A; Cho BC; Lemech CR; De Souza PL; Millward M; Choi JY; Park KE; Kim NY; Kim E; Lee S; Kim Y; Shin Y; Han J-Y, 2022, 'A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

To M; Merchant N; Coello M; Galligan C; Mehta K; Atkinson V; Bexon M; Coward J; Lee J; Lemech C; Lloyd P; Antras J; Yavari A; Merchant F, 2022, '743 Pharmacokinetic and pharmacodynamic profile of a first-in-human study with MDNA11, an engineered long-acting beta-only IL-2 agonist', BMJ, pp. a776 - a776, presented at Regular and Young Investigator Award Abstracts, http://dx.doi.org/10.1136/jitc-2022-sitc2022.0743

To M; Merchant F; Atkinson V; Bexon M; Coward J; Lee J; Lemech C; Antras J; Lloyd P; Yavari A; Coello M; Merchant N, 2022, '744 Interim single-agent safety and anti-tumor activity from dose escalation phase of ABILITY study on MDNA11, a long-acting beta-only IL-2 agonist', BMJ, pp. a777 - a777, presented at Regular and Young Investigator Award Abstracts, http://dx.doi.org/10.1136/jitc-2022-sitc2022.0744

White S; Lemech C; Hari R; Kruger N; McLachlan G; Demaison C; Mercuri F, 2022, 'Safety and Tolerability of the Toll-Like Receptor (TLR)2/6 Agonist INNA-051 in Healthy Adults', in American Journal of Respiratory and Critical Care Medicine, Oxford University Press (OUP), pp. a2598 - a2598, presented at B31. IMMUNE CELLS AND INFLAMMATORY PATHWAYS DRIVING LUNG INJURY AND INFECTION - VIEWS FROM THE BENCH, http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2598

Lemech C; Dredge K; Bampton D; Hammond E; Clouson A; Waterhouse N; Stanley A; Leveque-ElMouttie L; Chojnowski G; Haydon A; Pavlakis N; Burge M; Brown M; Goldstein D, 2021, 'A PHASE IB EXPANSION COHORT OF PIXATIMOD PLUS NIVOLUMAB IN PREVIOUSLY TREATED, MICROSATELLITE STABLE METASTATIC COLORECTAL CANCER (MSS MCRC)', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A367 - A367, http://dx.doi.org/10.1136/jitc-2021-SITC2021.341

Lemech C; Dredge K; Bampton D; Hammond E; Stanley A; Leveque-ElMouttie L; Chojnowski G; Haydon A; Pavlakis N; Burge M; Brown M; Goldstein D, 2021, 'A PHASE IB STUDY OF THE SAFETY AND TOLERABILITY OF PIXATIMOD PLUS NIVOLUMAB IN SUBJECTS WITH ADVANCED SOLID TUMORS WITH AN EXPANSION COHORT IN METASTATIC PANCREATIC ADENOCARCINOMA (MPDAC)', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A366 - A366, http://dx.doi.org/10.1136/jitc-2021-SITC2021.340

Coward J; Lemech CR; Mislang ARA; Parakh S; Underhill C; Nagrial A; Jin X; Li B; Wang ZM; Kwek KY; Xia Y, 2020, 'A phase I study of AK112, a bispecific antibody that targets PD-1 and VEGF co-expressing T cells, in patients with advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368309070&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Tran B; Horvath L; Dorff T; Rettig M; Lolkema MP; Machiels J-P; Rottey S; Autio K; Greil R; Adra N; Lemech C; Minocha M; Cheng F-C; Kouros-Mehr H; Fizazi K, 2020, 'Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)', in Annals of Oncology, Elsevier, pp. s507, http://dx.doi.org/10.1016/j.annonc.2020.08.869

Unnikrishnan A; Lim XY; Joshi S; Nunez AC; Vaughan L; Pickford R; Hough S; Davidson S; Fong C; Kenealy M; Hiwase DK; Pasalic L; Mohammed S; Lee L; Passam FH; Spring K; Rebeiro P; Ling S; Fuller S; Presgrave P; Roncolato F; Larsen S; Enjeti AK; Stevenson WS; Tiley C; Campbell PJ; Lemech C; Olivier J; Hertzberg M; Polizzotto MN; Pimanda J, 2019, 'In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial', in Blood, American Society of Hematology, pp. 4247, http://dx.doi.org/10.1182/blood-2019-123921

Kuo J; Bampton D; Lemech CR; Brown MP; Stanley A; Chojnowski G; Hammond E; Dredge K; Goldstein D, 2018, 'Preliminary results from a Phase Ib study of pixatimod (PG545) in combination with nivolumab in patients with advanced solid tumours with an expansion cohort in patients with metastatic pancreatic cancer', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, IRELAND, Dublin, pp. E18 - E19, presented at 30th EORTC-NCI-AACR Symposium, IRELAND, Dublin, 13 November 2018 - 16 November 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000461258600037&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kuo JC; Roncolato FT; Bahari B; Wharton J; Lemech CR, 2018, 'Conducting early-phase oncology clinical trials: Experience of a dedicated clinical trial unit', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 154 - 155, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000449544200254&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Plesner T; Arkenau H-T; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; Yeh H; Ahmadi T; Lokhorst HM; Richardson PG, 2015, 'Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)', in Blood, American Society of Hematology, pp. 507, http://dx.doi.org/10.1182/blood.v126.23.507.507

Plesner T; Arkenau HT; Lokhorst HM; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Ahmadi T; Yeh H; Guckert M; Brun NC; Lisby S; Basse L; Palumbo A; Richardson PG, 2014, 'SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA', in HAEMATOLOGICA, FERRATA STORTI FOUNDATION, ITALY, Milan, pp. 104 - 104, presented at 19th Congress of the European-Hematology-Association, ITALY, Milan, 12 June 2014 - 15 June 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000342830900251&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lemech CR; Ensell L; Paterson J; Eminowicz G; Lowe H; Griffin N; Arora R; Arkenau H-T; Widschwendter M; MacDonald N; Olaitan A; Mould T; Meyer T; Hartley JA; Mitra A; Ledermann JA; McCormack M; Kristeleit RS, 2014, 'Feasibility of circulating tumour cell (CTC) enumeration and molecular profiling (MP) as a biomarker in advanced endometrial cancer (aEC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.5600

Arkenau H-T; Saggese M; Hollebecque A; Mathewson A; Lemech CR; Landers D; Frewer P; Kilgour E; Brooks N, 2014, 'A phase 1 expansion cohort of the fibroblast growth factor receptor (FGFR) inhibitor AZD4547 in patients (pts) with advanced gastric (GC) and gastroesophageal (GOJ) cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), pp. 2620 - 2620, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.2620

Arkenau H-T; Mateo J; Lemech CR; Infante JR; Burris HA; Bang Y-J; Eder JP; Herbst RS; Sharma S; Chung HC; Decordova S; Swales KE; Garrett MD; Loftiss JI; Durante M; Russo MW; Suttle BB; Motwani M; Kumar R; De Bono JS, 2014, 'A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), pp. 2514 - 2514, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.2514

Plesner T; Arkenau H-T; Lokhorst HM; Gimsing P; Krejcik J; Lemech CR; Minnema M; Lassen UN; Ahmadi T; Yeh H; Guckert M; Brun NC; Lisby S; Basse L; Palumbo A; Richardson PG, 2014, 'Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), pp. 8533 - 8533, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.8533

Plesner T; Arkenau T; Lokhorst H; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Cakana A; Brun NC; Basse L; Palumbo A; Richardson PG, 2013, 'Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma', in BLOOD, AMER SOC HEMATOLOGY, LA, New Orleans, presented at 55th Annual Meeting of the American-Society-of-Hematology, LA, New Orleans, 07 December 2013 - 10 December 2013

Lemech CR; Newmark J; Arkenau H-T, 2013, 'The use of molecular profiling (MP) beyond standard panels in day-to-day practice: A multi-institutional multinational survey', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419604404&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Soria J-C; Gan HK; Arkenau H-T; Blagden SP; Plummer R; Ranson M; Evans TRJ; Zalcman G; Bahleda R; Hollebecque A; Lemech C; Brown J; Peddareddigari VGR; Gibson D; Murray SC; Nebot N; Mazumdar J; Fleming RA; Millward M, 2012, 'Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009802283&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lemech CR; Fontela A; Arkenau H-T; Chin MTM; Li S; Liauw WS; Thomas D; De Souza PL, 2012, 'Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 01 June 2012 - 06 June 2012, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000318009802330&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lemech CR; Cosman R; Lee C; Friedlander M; Lewis C; Lynch J; Thomas D; Clingan P; Glasgow A, 2010, 'Cardiac dysfunction in patients receiving trastuzumab for early stage breast cancer in the SESIAHS', in Aisa-Pacific Journal of Clinical Oncology, Sydney Australia, presented at Medical Oncology Group of Australia Annual Scientific Meeting, Sydney Australia, 12 August 2010 - 14 August 2010, http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2010.01301.x/epdf

Conference Posters

Baird RD; Cresti N; Beddowes E; Saggese M; Flynn M; Garcia Corbacho J; Gao F; Lemech CR; Donaldson K; Posner J; Kawabat I; Forster M; Arkenau HT; Plummer R; Jodrell D; Spicer J, 2013, 'Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily pre-treated HER2-positive metastatic breast cancer', presented at San Antonio Breast Cancer Symposium, 10 December 2013 - 14 December 2013, http://www.abstracts2view.com/sabcs13/viewp.php?nu=P4-12-24

Dua D; Lemech CR; Newmark J; Saggese M; Spiliopoulou P; Ash N; Williams I; Hauser J; Lauigan M; Muzengi M; Arkenau HT, 2013, 'Patients' perceptions of research biopsies on early phase oncology trials', Liverpool UK, presented at NCRI Cancer Conference, Liverpool UK, 03 November 2013 - 06 November 2013

Lemech CR; Newmark J; Arkenau HT, 2013, 'The use of molecular profiling (MP) beyond standard panels in day-to-day practice - a multi-institutional multi-national survey', Liverpool UK, presented at NCRI Cancer Conference, Liverpool UK, 03 November 2013 - 06 November 2013, http://conference.ncri.org.uk/abstracts/2013/abstracts/B101.htm

Ganguli S; Spiliopoulou P; Benafif S; Flynn M; Lemech CR; Saggese M; Forster M; Kristeleit R; Arkenau HT; Meyer T, 2013, 'Clinical outcomes for patients in early phase clinical trials: the UCLH and Sarah Cannon Research UK experience', Liverpool UK, presented at NCRI Cancer Conference, Liverpool UK, 03 November 2013 - 06 November 2013, http://conference.ncri.org.uk/abstracts/2013/abstracts/B65.htm

Liauw W; Lemech CR, 2010, 'Diffuse peritoneal adenomucinosis in a patient wiht familial adenomatous polyposis', Melbourne, Victoria, Australia, presented at Clinical Oncology Society of Australia Annual Scientific Meeting, Melbourne, Victoria, Australia, 09 November 2010 - 11 November 2010

Lemech CR; Friedlander M, 2009, 'Clear cell cancer of the ovary: from resistance to response', Canberra Australia, presented at MOGA Annual Scientific Meeting, Canberra Australia, 12 August 2009 - 14 August 2009, http://onlinelibrary.wiley.com/doi/10.1111/j.1743-7563.2009.01218.x/pdf

Conference Abstracts

Lemech CR; Wei J; Chawla SP; Dumbrava EE; Sharma S; Kim SY; Schmidt AL; Bishnoi SK; Gundala S; Rastogi S; Prabash K; Jain MM; Inamdar SP; Chimote G; Sreenivasan J, 2026, 'A phase 1, multicenter, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of SBO-154 in subjects with advanced solid tumors.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 44, pp. tps3161 - tps3161, http://dx.doi.org/10.1200/jco.2026.44.16_suppl.tps3161

Lemech CR; Zhou C; Park JJ; Gao B; Guo S; Fang J; Coward JIG; Moore MA; Zhang P; Yu Y; Frentzas S; Dong X; Liu H; Wang J; Wang Q; Fang T; Wang B; Dai H; Shi Q; Yang J, 2026, 'CS2009, a novel PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors: Updated results from an open-label, multicenter, phase 1 first-in-human study.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 44, pp. 2521 - 2521, http://dx.doi.org/10.1200/jco.2026.44.16_suppl.2521

Ryu M-H; Lemech CR; Ganju V; Bulat I; Lee C-K; Park JO; Khattak A; Roohullah A; Kang B; Zhao Z; Kalman T; Wang S; Yang Q; Chao BH; Nagrial A, 2026, 'A global phase 1/2a trial of SHR-A1904, a CLDN18.2-targeting ADC, in advanced solid tumors expressing CLDN18.2', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 44, pp. e15018 - e15018, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 29 May 2026 - 02 June 2026, http://dx.doi.org/10.1200/JCO.2026.44.16_suppl.e15018

Back to profile page